Brief: Acumen Pharmaceuticals Completes Enrollment In Phase 1 Trial Of ACU193

Acumen Pharmaceuticals

13/02/2023 13:37

Feb 13 (Reuters) - Acumen Pharmaceuticals Inc  ABOS.O :
    * ACUMEN PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE 1
TRIAL OF
ACU193, FIRST MONOCLONAL ANTIBODY DEVELOPED TO SELECTIVELY
TARGET TOXIC AΒ OLIGOMERS IN PATIENTS WITH EARLY ALZHEIMER’S
DISEASE
    * ACUMEN PHARMACEUTICALS INC - ON TRACK TO REPORT TOPLINE
RESULTS,
INCLUDING SAFETY AND PROOF-OF-MECHANISM DATA, IN Q3 OF 2023

Source text for Eikon:  ID:nGNX9Z43F8 
Further company coverage:  ABOS.O 
 ((Reuters.Briefs@thomsonreuters.com;))